@article{fd18570a0ac94c7a8a05d8ae64de25dd,
title = "Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature Review",
keywords = "Compound mutations, Epithelial growth factor receptor, Non–small-cell lung cancer, Osimertinib, Uncommon mutations",
author = "Yuanyuan Zhao and Linzhu Zhai and Lei Deng and Balazs Halmos and Haiying Cheng",
note = "Funding Information: B.H. has received research funding and consulting fees from both Boehringer Ingelheim and AstraZeneca. H.C. has received research funding and honoraria from AstraZeneca. The remaining authors have stated that they have no conflicts of interest.",
year = "2021",
month = may,
doi = "10.1016/j.cllc.2020.06.017",
language = "English (US)",
volume = "22",
pages = "e466--e469",
journal = "Clinical lung cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "3",
}
